CAM
AKBA icon

Cresset Asset Management’s Akebia Therapeutics AKBA Stock Holding History

Cresset Asset Management’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-142
Closed -$1K – 507
2019
Q1 		$1K Hold
142
– – ﹤0.01% 1752
2018
Q4 		$1K Buy
+142
New +$1.11K ﹤0.01% 1450

Other funds holding AKBA

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cresset Asset Management's AKBA Position: Q2 2019 in Review

Cresset Asset Management sold out of Akebia Therapeutics (AKBA) in Q2 2019, closing a stake of 142 shares — an estimated $1K sold.

Cresset Asset Management first reported a position in AKBA in Q4 2018 and held it in 2 quarters. The position peaked at $1K in Q1 2019. 151 funds tracked by Wall St. Rank hold AKBA as of Q2 2019.

  • Cresset Asset Management reported no remaining Akebia Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Cresset Asset Management sold 142 Akebia Therapeutics shares in Q2 2019, an estimated $1K.
  • Cresset Asset Management first reported a position in Akebia Therapeutics in Q4 2018 and held it in 2 quarters.
  • Cresset Asset Management's Akebia Therapeutics position peaked at $1K in Q1 2019.
  • 151 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2019.

Based on Cresset Asset Management's 13F filing for Q2 2019, filed 12 Aug 2019.